Receptor mechanisms in antipsychotic drug action: focus on sigma receptors
Abstract
The principal antischizophrenic neuroleptic drugs in current clinical use act by blocking dopamine receptors, which mediate extrapyramidal side effects and tardive dyskinesia. As an alternative strategy, researchers have sought agents that do not influence dopamine receptors but whose behavioral effects in animals resemble those of neuroleptics. Some promising "new generation" candidate drugs have shown beneficial effects in schizophrenic patients in early clinical trials. These new agents share a selective, high affinity for sigma receptors, sites where psychotomimetic opiates act. A systematic screen for drugs that block sigma receptors may provide a valuable strategy in identifying novel antischizophrenic agents and in clarifying the pathophysiology of psychosis.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).
